Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated February 10, 2023, reports a significant regulatory milestone for the company's oncology portfolio. The filing details the US Food and Drug Administration (FDA) granting regular (full) approval for Jemperli (dostarlimab-gxly) for the treatment of adult patients with mismatch repair-deficient (dMMR) recurrent or advanced endometrial cancer.
Key Financial Metrics
This filing is a regulatory announcement and does not contain financial statements. Consequently, there are no reported values for revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes and Clinical Data
The primary material change is the conversion of Jemperli's status from accelerated approval to regular approval for dMMR endometrial cancer. This decision was based on long-term outcomes from the GARNET phase I trial (Cohort A1), which evaluated 141 patients. Key clinical metrics include:
- Overall Response Rate (ORR): 45.4% (95% CI: 37.0, 54.0).
- Complete Response Rate: 15.6%.
- Partial Response Rate: 29.8%.
- Duration of Response (DOR): Median not reached (range: 1.2+ to 52.8+ months).
- Durability: 85.9% of patients had a duration of response ≥12 months; 54.7% had a duration ≥24 months.
- Median Follow-up: 27.9 months.
Outlook, Management Commentary, and Risks
Management Commentary: Hesham Abdullah, Senior Vice President of Global Head of Oncology Development, stated that the approval confirms confidence in Jemperli as an important treatment option. GSK aims to position Jemperli as the backbone of its immuno-oncology development programs to address unmet needs in earlier lines of endometrial cancer and other solid tumors.
Outlook: Jemperli is being investigated in registrational studies as monotherapy and in combination regimens for recurrent or primary advanced endometrial cancer, Stage III or IV non-mucinous epithelial ovarian cancer, and other advanced solid tumors.
Risks and Contingencies: The filing includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ due to risks described in the 2021 Form 20-F, Q4 2022 results, and the impact of the COVID-19 pandemic. Additionally, the accelerated approval for dMMR solid tumors (non-endometrial) remains contingent upon verification of clinical benefit in confirmatory trials.
Investor Verification Checklist
- Verify the commercial launch timeline and pricing strategy for Jemperli under the new full approval indication.
- Review the status of ongoing confirmatory trials for the accelerated approval indication in non-endometrial solid tumors.
- Monitor enrollment and data readouts for combination therapy trials involving Jemperli in ovarian cancer and earlier-line endometrial cancer.
- Assess the competitive landscape for dMMR endometrial cancer treatments following this regulatory milestone.